Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

被引：0
作者：
Robert M Eager
C Casey Cunningham
Neil N Senzer
Joe Stephenson
Stephen P Anthony
Steven J O'Day
Gary Frenette
Anna C Pavlick
Barry Jones
Margaret Uprichard
John Nemunaitis
机构：
[1] Mary Crowley Cancer Research Centers,Clinical Research Unit
[2] Texas Oncology PA,Department of Dermatology
[3] Baylor Sammons Cancer Center,Department of Internal Medicine
[4] Gradalis,undefined
[5] Inc,undefined
[6] Cancer Centers of the Carolinas,undefined
[7] Cancer Care Northwest,undefined
[8] The Angeles Clinic and Research Institute,undefined
[9] Carolinas Medical Center,undefined
[10] New York University Clinical Cancer Center,undefined
[11] Point Therapeutics,undefined
[12] Inc,undefined
[13] The University of Hawaii,undefined
来源：
BMC Cancer | / 9卷
关键词：
Metastatic Melanoma; Evaluable Patient; Dipeptidyl Peptidase; Fibroblast Activation Protein; Index Lesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
    Lu, Brandon
    Dai, Wei Fang
    Croxford, Ruth
    Isaranuwatchai, Wanrudee
    Beca, Jaclyn
    Menjak, Ines B.
    Petrella, Teresa M.
    Mittmann, Nicole
    Earle, Craig C.
    Gavura, Scott
    Mercer, Rebecca E.
    Hanna, Timothy P.
    Chan, Kelvin K. W.
    CANCER MEDICINE, 2023, 12 (10): : 11451 - 11461
  • [32] Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada
    Dai, Wei Fang
    Beca, Jaclyn
    Croxford, Ruth
    Isaranuwatchai, Wanrudee
    Menjak, Ines B.
    Petrella, Teresa M.
    Mittmann, Nicole
    Earle, Craig C.
    Gavura, Scott
    Mercer, Rebecca E.
    Hanna, Timothy P.
    Chan, Kelvin K. W.
    INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (08) : 1910 - 1918
  • [33] Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group
    Bafaloukos, D
    Tsoutsos, D
    Kalofonos, H
    Chalkidou, S
    Panagiotou, P
    Linardou, E
    Briassoulis, E
    Efstathiou, E
    Polyzos, A
    Fountzilas, G
    Christodoulou, C
    Kouroussis, C
    Iconomou, T
    Gogas, H
    ANNALS OF ONCOLOGY, 2005, 16 (06) : 950 - 957
  • [34] A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma
    Schultz, MZ
    Buzaid, AC
    Poo, WJ
    MELANOMA RESEARCH, 1997, 7 (02) : 147 - 151
  • [35] OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study
    Cui, ChuanLiang
    Wang, Xuan
    Lian, Bin
    Ji, Qing
    Zhou, Li
    Chi, Zhihong
    Si, Lu
    Sheng, Xinan
    Kong, Yan
    Yu, Jiayi
    Li, Siming
    Mao, Lili
    Tang, Bixia
    Dai, Jie
    Yan, Xieqiao
    Bai, Xue
    Andtbacka, Robert
    Guo, Jun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [36] Age Has No Significant Impact on Overall Survival and on Treatment Tolerability in Relapsed Stage IV Cutaneous Malignant Melanoma Patients Receiving Cisplatin, Gemcitabine, and Treosulfan
    Atzpodien, Jens
    Terfloth, Kerstin
    Fluck, Michael
    Reitz, Martina
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (01): : 2 - 5
  • [37] Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma
    Plummer, R.
    Lorigan, P.
    Brown, E.
    Zaucha, R.
    Moiseyenko, V.
    Demidov, L.
    Soriano, V.
    Chmielowska, E.
    Andres, R.
    Kudryavtseva, G.
    Kahatt, C.
    Szyldergemajn, S.
    Extremera, S.
    de Miguel, B.
    Cullell-Young, M.
    Calvert, H.
    BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1451 - 1459
  • [38] A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma
    Poschke, Isabel
    Lovgren, Tanja
    Adamson, Lars
    Nystrom, Maria
    Andersson, Emilia
    Hansson, Johan
    Tell, Roger
    Masucci, Giuseppe V.
    Kiessling, Rolf
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (10) : 1061 - 1071
  • [39] Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
    Marsavela, Gabriela
    Lee, Jenny
    Calapre, Leslie
    Wong, Stephen Q.
    Pereira, Michelle R.
    McEvoy, Ashleigh C.
    Reid, Anna L.
    Robinson, Cleo
    Warburton, Lydia
    Abed, Afaf
    Khattak, Muhammad A.
    Meniawy, Tarek M.
    Dawson, Sarah-Jane
    Sandhu, Shahneen
    Carlino, Matteo S.
    Menzies, Alexander M.
    Scolyer, Richard A.
    Long, Georgina, V
    Amanuel, Benhur
    Millward, Michael
    Ziman, Melanie R.
    Rizos, Helen
    Gray, Elin S.
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5926 - 5933
  • [40] Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
    Ridolfi, Laura
    de Rosa, Francesco
    Fiammenghi, Laura
    Petrini, Massimiliano
    Granato, Anna Maria
    Ancarani, Valentina
    Pancisi, Elena
    Soldati, Valentina
    Cassan, Serena
    Bulgarelli, Jenny
    Riccobon, Angela
    Gentili, Giorgia
    Nanni, Oriana
    Framarini, Massimo
    Tauceri, Francesca
    Guidoboni, Massimo
    BMJ OPEN, 2018, 8 (08):
12345